Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Rheumatology

• Publication date

  1998-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 9489824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-6 family of cytokines and gp130.

  1995cited by this paper
• Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts.

  1995cited by this paper
• ELISA Detection of Circulating Levels of LIF, OSM, and CNTF in Septic Shock

  1995cited by this paper
• Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome.

  1994cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy

  1993cited by this paper
• Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.

  1992cited by this paper
• Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo.

  1992cited by this paper
• Up‐regulation of interleukin (IL)‐6 receptor gene expression in vitro and in vivo in IL‐6 deprived myeloma cells

  1992cited by this paper
• Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

  1992cited by this paper
• Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.

  1992cited by this paper
• Regulation of IL-6 expression by oncostatin M.

  1991cited by this paper
• Measurement of interleukin‐6 in bronchoalveolar lavage fluid by radioimmunoassay: differences between patients with interstitial lung disease and control subjects

  1991cited by this paper
• Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

  1991cited by this paper
• Biological and clinical aspects of interleukin 6.

  1990cited by this paper
• Fate of interleukin-6 in the rat. Involvement of skin in its catabolism.

  1990cited by this paper
• In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis

  1990cited by this paper
• Molecular cloning and expression of an IL-6 signal transducer, gp130.

  1990cited by this paper
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper
• Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

  1988cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells.

  1987cited by this paper
• Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells.

  1986cited by this paper

• Emerging therapies for the treatment of systemic sclerosis

  2025cites this paper
• Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis.

  2025cites this paper
• Fibrosis mechanisms in systemic sclerosis and new potential therapies.

  2024cites this paper
• The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis

  2023cites this paper
• IL-6 trans-signaling in a humanized mouse model of scleroderma

  2023cites this paper
• Evaluation of expression pattern of cellular miRNAs (let-7b, miR-29a, miR-126, miR-34a, miR-181a-5p) and IL-6, TNF-α, and TGF-β in patients with pseudoexfoliation syndrome.

  2023cites this paper
• Peripheral blood IL‐6 levels in systemic sclerosis patients: Correlation between IL‐6 levels and clinical phenotypes

  2022cites this paper
• Molecular pathogenesis of fibrosis in systemic sclerosis

  2022cites this paper
• Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration

  2022cites this paper
• Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

  2022influential citation
• New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics

  2022cites this paper
• Role of B-Cell in the Pathogenesis of Systemic Sclerosis

  2022cites this paper
• Oncostatin M Counteracts the Fibrotic Effects of TGF-β1 and IL-4 on Nasal-Polyp-Derived Fibroblasts: A Control of Fibrosis in Chronic Rhinosinusitis with Nasal Polyps?

  2022cites this paper
• Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells

  2021cites this paper
• RAGE-mediated functional DNA methylated modification contributes to cigarette smoke-induced airway inflammation in mice

  2021cites this paper
• Association of Serum IL 6 with Different Clinical Presentations of Systemic Sclerosis Patients: A Case-Control Study

  2021cites this paper
• Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps

  2021cites this paper
• Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis

  2021cites this paper
• Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy

  2021cites this paper
• Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives

  2020cites this paper
• Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters.

  2020cites this paper
• Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice

  2020cites this paper
• The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis

  2020cites this paper
• Fat Grafting for the Treatment of Scleroderma.

  2019cites this paper
• Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature

  2019cites this paper
• The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis

  2019cites this paper
• Adipose‐derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models

  2019cites this paper
• Interleukin 11 expression causes murine inflammatory bowel disease

  2019cites this paper
• IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis

  2018cites this paper
• Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu

  2018cites this paper
• Use of tocilizumab in systemic sclerosis: A brief literature review.

  2018cites this paper
• Rôle de la réponse immunitaire de type 2 dans la réparation tissulaire : du concept au modèle pratique de la sclérodermie systémique

  2018cites this paper
• Use of tocilizumab in systemic sclerosis: A brief literature review

  2018cites this paper
• Novel classification for global gene signature model for predicting severity of systemic sclerosis

  2018cites this paper
• Inflammation and Immunity

  2017cites this paper
• The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.

  2017cites this paper
• Critical contribution of the interleukin‐6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis

  2017cites this paper
• A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis

  2017cites this paper
• Oncostatin M: Potential Implications for Malignancy and Metabolism.

  2017cites this paper
• Use of biologics and other novel therapies for the treatment of systemic sclerosis

  2017cites this paper
• Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

  2017cites this paper
• Interleukin-6 and Related Proteins as Biomarkers in Systemic Sclerosis

  2017cites this paper
• Biologic treatments for pulmonary involvement in rheumatic disease

  2016cites this paper
• Interleukin-6 in the Pathogenesis of Systemic Sclerosis

  2016cites this paper
• Targeted Therapy in Systemic Sclerosis

  2016cites this paper
• Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells

  2016cites this paper
• Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis

  2016cites this paper
• Autoimmunity in Systemic Sclerosis: Overview

  2016cites this paper
• Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis

  2016cites this paper
• Elevated Serum BAFF Levels in Patients with Systemic Sclerosis (SSc): Enhanced BAFF Signaling in SSc B Lymphocytes

  2016influential citation
• Annotating PDFs using Adobe Reader XI

  2016cites this paper
• Strategy for treatment of fibrosis in systemic sclerosis: Present and future

  2016cites this paper
• CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis

  2016cites this paper
• Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement

  2015cites this paper
• Paget’s disease of bone: an osteoimmunological disorder?

  2015cites this paper
• From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.

  2015cites this paper
• Therapeutic Interventions in Oral Submucous Fibrosis: An Experimental and Clinical Study

  2015cites this paper
• Immungenetische Untersuchung zur Assoziation des Promotor Polymorphismus des Interleukin-6-Gens in Position -174G/C bei Patienten mit systemischer Sklerodermie

  2015cites this paper
• Molecular Biomarkers in Interstitial Lung Diseases

  2014cites this paper
• Fibrosis—a lethal component of systemic

  2014cites this paper
• Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance

  2014cites this paper
• Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

  2014cites this paper
• Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition

  2014cites this paper
• Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor

  2014cites this paper
• Novel investigational agents for the treatment of scleroderma

  2014cites this paper
• Fibrosis—a lethal component of systemic sclerosis

  2014cites this paper
• Systemic Sclerosis, Scleroderma

  2014cites this paper
• B-Cell Targeted Therapies in Systemic Sclerosis and Inflammatory Myopathies

  2014cites this paper
• CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING IN PULMONARY FIBROSIS

  2014cites this paper
• Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis

  2014cites this paper
• Pulmonary Fibrosis Signaling Attenuates Trans Blockade of IL-6

  2014cites this paper
• This information is current as Pulmonary Fibrosis Signaling Attenuates Trans Blockade of IL-6 and

  2014cites this paper
• Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab

  2013cites this paper
• Agonistic anti-ICAM-1 antibodies in scleroderma: Activation of endothelial pro-inflammatory cascades

  2013cites this paper
• Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

  2013cites this paper
• Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

  2013cites this paper
• Scleroderma Lung Fibrosis and Biologic Drugs

  2012cites this paper
• Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases.

  2012cites this paper
• Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.

  2012cites this paper
• Therapeutic targeting of the interleukin-6 receptor.

  2012cites this paper
• Racial differences between blacks and whites with systemic sclerosis

  2012cites this paper
• Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group

  2012cites this paper
• Immunotherapeutic implication of IL-6 blockade.

  2012cites this paper
• Prognosis of scleroderma renal crisis: a long-term observational study.

  2012cites this paper
• Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis

  2012cites this paper
• IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.

  2012cites this paper
• Systemic Sclerosis 2011

  2012cites this paper
• Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy

  2012cites this paper
• Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

  2012cites this paper
• Scleroderma

  2012cites this paper
• Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions

  2012cites this paper
• Three Cases of Sarcoidosis with Collagen Vascular Diseases

  2012cites this paper
• Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders

  2011cites this paper
• Allograft inflammatory factor-1 is overexpressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model.

  2011cites this paper
• Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

  2011cites this paper
• The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis

  2011cites this paper
• Caractérisation de l'interaction de l'auto-antigène ADN topoisomérase I avec les fibroblastes dans la sclérose systémique

  2011cites this paper
• Влияние аторвастатина на динамику маркеров воспаления при системной склеродермии

  2011cites this paper
• Cytokine profiles in localized scleroderma and relationship to clinical features.

  2011cites this paper
• [Pleiotropic effects of statins in systemic sclerosis].

  2011cites this paper